41010-49-5Relevant academic research and scientific papers
Novel imidazo[4,5-b]pyridine derived acrylonitriles: A combined experimental and computational study of their antioxidative potential
Bo?ek, Ida,Hranjec, Marijana,Novak Jovanovi?, Ivana,Star?evi?, Kristina,Vianello, Robert
, (2021/09/22)
We describe the synthesis of novel unsubstituted and N-substituted imidazo[4,5-b]pyridine derived acrylonitriles, which were prepared by classical and microwave assisted organic synthesis. Their antioxidative potential was studied using spectroscopic DPPH
Heterocyclic compound and organic light emitting device including the same
-
Paragraph 0521; 0534-0537; 0628; 0633-0636, (2020/07/15)
Provided are a heterocyclic compound and an organic light-emitting device including the same. The heterocyclic compound may be represented by Formula 1: in the Formula 1, A1, X2, Y1, Y2, m1, m2, R10,R20, R30, b10, b20 and b30 are same as described in the description.
Platinum compound with photoluminescence performance and preparation method thereof
-
Paragraph 0049; 0052; 0054; 0059; 0061; 0066; 0068, (2020/11/23)
The invention belongs to the technical field of organic complex synthesis, and particularly relates to a platinum compound with photoluminescence performance and a preparation method thereof. The molecular formula of the platinum compound with the photolu
Pt (II) photoluminescence compound based on pyridinoimidazole derivative and preparation method thereof
-
Paragraph 0057; 0059; 0064; 0066; 0071; 0073, (2020/12/15)
The invention belongs to the technical field of synthesis of organic complexes, and particularly relates to a Pt (II) photoluminescence compound based on a pyridinoimidazole derivative and a preparation method thereof. The molecular formula of the Pt (II)
Platinum luminescent compound based on pyridinoimidazole derivative and preparation method of platinum luminescent compound
-
Paragraph 0050; 0053; 0055; 0060; 0062; 0067; 0069, (2020/12/15)
The invention belongs to the technical field of synthesis of organic complexes, and particularly relates to a platinum luminescent compound based on a pyridinoimidazole derivative and a preparation method of the platinum luminescent compound. The molecula
Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents
Prasad, Budaganaboyina,Lakshma Nayak,Srikanth,Baig, Mirza Feroz,Subba Reddy,Babu, Korrapati Suresh,Kamal, Ahmed
, p. 535 - 548 (2018/11/26)
A library of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides (7a–al) have been designed, synthesized and screened for their anti-proliferative activity against some selected human cancer cell lines namely DU-145, A-549, MCF-7 and HeLa. Most of them have shown promising cytotoxicity against lung cancer cell line (A549), amongst them 7f was found to be the most potent anti-proliferative congener. Furthermore, 7f exhibited comparable tubulin polymerization inhibition (IC50 value 2.04 μM) to the standard E7010 (IC50 value 2.15 μM). Moreover, flow cytometric analysis revealed that this compound induced apoptosis via cell cycle arrest at G2/M phase in A549 cells. Induction of apoptosis was further observed by examining the mitochondrial membrane potential and was also confirmed by Hoechst staining as well as Annexin V-FITC assays. Furthermore, molecular docking studies indicated that compound 7f binds to the colchicine binding site of the β-tubulin. Thus, 7f exhibits anti-proliferative properties by inhibiting the tubulin polymerization through the binding at the colchicine active site and by induction of apoptosis.
Rational design and synthesis of 2-anilinopyridinyl-benzothiazole Schiff bases as antimitotic agents
Shaik, Thokhir B.,Hussaini, S.M. Ali,Nayak, V. Lakshma,Sucharitha, M. Lakshmi,Malik, M. Shaheer,Kamal, Ahmed
supporting information, p. 2549 - 2558 (2017/05/09)
Based on our previous results and literature precedence, a series of 2-anilinopyridinyl-benzothiazole Schiff bases were rationally designed by performing molecular modeling experiments on some selected molecules. The binding energies of the docked molecules were better than the E7010, and the Schiff base with trimethoxy group on benzothiazole moiety, 4y was the best. This was followed by the synthesis of a series of the designed molecules by a convenient synthetic route and evaluation of their anticancer potential. Most of the compounds have shown significant growth inhibition against the tested cell lines and the compound 4y exhibited good antiproliferative activity with a GI50 value of 3.8?μM specifically against the cell line DU145. In agreement with the docking results, 4y exerted cytotoxicity by the disruption of the microtubule dynamics by inhibiting tubulin polymerization via effective binding into colchicine domain, comparable to E7010. Detailed binding modes of 4y with colchicine binding site of tubulin were studied by molecular docking. Furthermore, 4y induced apoptosis as evidenced by biological studies like mitochondrial membrane potential, caspase-3, and Annexin V-FITC assays.
Synthesis of 2-anilinopyridine dimers as microtubule targeting and apoptosis inducing agents
Kamal, Ahmed,Ali Hussaini,Lakshma Nayak,Shaheer Malik,Lakshmi Sucharitha,Shaik, Thokhir Basha,Ashraf, Md.,Bagul, Chandrakant
, p. 6755 - 6767 (2015/02/02)
A series of 2-anilinopyridine dimers have been synthesized and evaluated for their anticancer potential. Most of the compounds have showed significant growth inhibition of the cell lines tested and compound 4d was most effective amongst the series display
Imidazopyridine derivatives as PI3K inhibitors
-
Page/Page column 32-33, (2012/11/13)
New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)
IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS
-
Page/Page column 80, (2012/11/13)
New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
